NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDPembrolizumab Keytruda®
(100mg/4ml concentrate for solution for infusion vials) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Pembrolizumab Pembrolizumab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
DSU June 2017: Nivolumab, pembrolizumab: reports of organ transplant rejection
MHRA Drug Safety Update (July 2017) -Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA1017: Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
NICE TA1037: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
NICE TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428 Pembrolizumab for treating PD-L1-positive NSC lung cancer
NICE TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA522 Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (NOT RECOMMENDED; partially replaced by TA967)
NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
NICE TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA692 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NOT RECOMMENDED
NICE TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
NICE TA766 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
NICE TA770 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
NICE TA801 Pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
NICE TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
NICE TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma
NICE TA837 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
NICE TA851 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
NICE TA858 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
NICE TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
NICE TA885 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939)
NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939)
NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
NICE TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
NICE TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma - NOT RECOMMENDED
NICE TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma